Marvel Biosciences Corp.

Marvel Biosciences Corp. (the “Company”) is a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug. Our business model capitalizes on significantly lower cost, less time and a lower risk profile to bring a drug asset to commercialization faster than the traditional long-term biotech model.

Recent News

  • Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression

    Calgary, Alberta--(Newsfile Corp. - January 6, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company " or "Marvel "), are pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices ("cGMP") of the active pharmaceutical ingredient (API) of the Company's lead asset MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The cGMP material obtained from this study will be utilized in the...

    2023-01-06 9:00 AM EST
  • Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204

    Calgary, Alberta--(Newsfile Corp. - January 3, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204. These studies will assist in determining the doses for the IND-enabling 4-week GLP toxicology studies."We are looking forward to initiating the 4-week toxicology studies early in 2023, which is the...

    2023-01-03 9:00 AM EST
  • Marvel Biosciences Announces Letter Agreement for Market Stabilization and Liquidity Services

    Calgary, Alberta--(Newsfile Corp. - December 23, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has entered into a Letter Agreement for Market Stabilization and Liquidity Services (the "Consulting Agreement") with Mr. Adam Smith of Red Cloud Securities Inc. ("Red Cloud") to support Marvel's market stabilization and liquidity activities.Marvel entered into the Consulting Agreement with Red Cloud effective December 1, 2022, with a...

    2022-12-23 4:30 PM EST
  • Marvel Biosciences Announces Stock Option Grant

    Calgary, Alberta--(Newsfile Corp. - December 20, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to a director to acquire 200,000 common shares in the capital of the Company at an exercise price of $0.135 being the closing price of the Company's common shares on the TSX Venture Exchange ("TSX-V") on December...

    2022-12-20 9:00 AM EST
  • Marvel Biosciences Initiates Its Final FDA-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate MB-204

    Calgary, Alberta--(Newsfile Corp. - December 12, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for its lead drug candidate MB-204.To date, the Company's MB-204 has shown positive and promising data addressing depression, anxiety as well as its potential benefit in protecting patient's vital organs while going through chemotherapy treatments. As the maximum tolerated single-dose studies have been...

    2022-12-12 9:00 AM EST
  • Marvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer's and Depression

    Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in preparation to initiate FDA Phase I human clinical trials."We have significantly de-risked the development of our lead drug candidate MB-204 and have a strong understanding of its safety...

    2022-12-07 9:00 AM EST
  • Marvel Biosciences Announces Director Appointment and Resignation

    Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, effective November 23, 2022, Mr. Babak Pedram has joined its Board of Directors.Babak Pedram, DirectorMr. Pedram brings a vast degree of business, capital markets and scientific experience to Marvel's Board of Directors. He is a seasoned capital market professional with over 15 years of experience as an investment...

    2022-11-24 5:36 PM EST
  • Marvel Biosciences' Lead Drug Candidate MB-204 Demonstrates a 400% Increase in the Survival Rate of Animals Treated with a High Dose of the Cancer Treatment Cis-Platinum

    Calgary, Alberta--(Newsfile Corp. - November 22, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that in a recent study done by the Company, its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment, cis-platinum."We are seeing great momentum being built around our lead drug candidate MB-204, which, as previously reported, ...

    2022-11-22 9:00 AM EST